Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin B (ICSI-CB)

Ibn Sina Hospital

Status: Completed

Conditions: Infertility

Treatments: Other: Cytochalasin B use in ICSI handling medium

Study type: Interventional

Funder types: Other

Identifiers

NCT03663634

IbnSinaIVF-ICSI-CB

Details and patient eligibility

About

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

Enrollment: 987 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All ICSI candidates patients

Exclusion criteria

• No exclusion

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

987 participants in 2 patient groups

Handling Medium Supplemented with Cytochalasin B

Experimental group

Treatment:

Other: Cytochalasin B use in ICSI handling medium

Handling Medium as it is.

No Intervention group